Iacovelli Roberto, Cannella Maria Antonella, Ciccarese Chiara, Astore Serena, Foschi Nazario, Palermo Giuseppe, Tortora Giampaolo
Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, Italy.
Department of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
Expert Rev Anticancer Ther. 2021 Nov;21(11):1203-1206. doi: 10.1080/14737140.2021.1976147. Epub 2021 Sep 9.
The 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium represents an unmissable event for oncologists who deal with renal cell carcinoma (RCC).
This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2α inhibitor belzutifan).
This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.
2021年美国临床肿瘤学会（ASCO）泌尿生殖系统癌症研讨会对于处理肾细胞癌（RCC）的肿瘤学家而言是一场不容错过的盛会。
本文描述了RCC治疗的主要进展，包括一种新的联合疗法（帕博利珠单抗+乐伐替尼）作为一线治疗的出现，在更长随访期内免疫检查点抑制剂（ICI）加血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKI）联合方案相对于舒尼替尼总生存期（OS）优势的确认，这些联合方案在特定亚组（具有肉瘤样分化的透明细胞转移性肾细胞癌肿瘤）中的持续获益，以及后续治疗线中的可能新方法（包括缺氧诱导因子-2α抑制剂贝佐蒂凡）。
2021年ASCO泌尿生殖系统癌症研讨会为转移性肾细胞癌日益个性化管理所需的进一步知识发展奠定了基础。
